临床试验:地中海饮食在肠易激综合征中可行并改善胃肠道和心理症状
这项非盲法6周随机对照试验纳入59例罗马IV肠易激综合征伴轻中度焦虑和/或抑郁症状的成人,比较地中海饮食咨询与习惯饮食。地中海饮食组第6周地中海饮食依从性筛查评分更高,胃肠道症状应答者和抑郁应答者比例均高于对照组,FODMAP摄入和不良事件无差异,微生物组参数变化无组间差异。
要点
- 地中海饮食组第6周地中海饮食依从性筛查评分为7.5,高于对照组的5.7(p < 0.001)。
- 地中海饮食组胃肠道症状应答24/29(83%),高于对照组的11/30(37%)(p < 0.001)。
- 地中海饮食组抑郁应答15/29(52%),高于对照组的6/30(20%)(p = 0.015)。
核心结论
- 地中海饮食在肠易激综合征中可行,并改善胃肠道和心理症状。
- 尽管研究为非盲法,这些发现结合地中海饮食的更广泛益处,为未来在肠易激综合征中的研究提供了强大动力。
研究设计与样本
- 非盲法6周随机对照试验,招募罗马IV肠易激综合征伴轻中度焦虑和/或抑郁症状的成人。
- 随机分配至地中海饮食咨询组或习惯饮食组,共随机59例(地中海饮食组29例,对照组30例),48例完成研究。
- 收集胃肠道和心理症状数据、饮食数据和粪便样本用于宏基因组测序。
主要发现
- 第6周地中海饮食依从性筛查评分地中海饮食组为7.5(95%CI:6.9-8.0),对照组为5.7(95%CI:5.2-6.3),p < 0.001。
- 评分增加幅度地中海饮食组为2.1(95%CI:1.3-2.9),对照组为0.5(95%CI:0.1-1.0),p = 0.004。
- 胃肠道症状应答者比例地中海饮食组为24/29(83%),对照组为11/30(37%),p < 0.001。
- 抑郁应答者比例地中海饮食组为15/29(52%),对照组为6/30(20%),p = 0.015。
- 第6周FODMAP摄入无差异(p = 0.51),胃肠道不良事件相似(p = 0.588),微生物组参数变化无组间差异。
局限性
- 本研究为非盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diet is fundamental to the care of irritable bowel syndrome (IBS). However, some approaches are not appropriate for individuals experiencing psychological symptoms. AIMS: To assess feasibility of a Mediterranean diet in IBS and its impact on gastrointestinal and psychological symptoms. METHODS: We recruited adults with Rome IV IBS and mild or moderate anxiety and/or depressive symptoms to an unblinded 6-week randomised controlled trial. Patients were randomised to Mediterranean diet counselling or habitual diet. We collected gastrointestinal and psychological symptom data, dietary data and stool samples for metagenomic sequencing. RESULTS: We randomised 59 individuals (29 Mediterranean diet, 30 control); 48 completed the study. The Mediterranean Diet Adherence Screener score was higher in the Mediterranean diet group than controls at week 6 (7.5 [95% CI: 6.9-8.0] vs. 5.7 [5.2-6.3], p < 0.001), and there was a greater score increase than controls (2.1 [95% CI: 1.3-2.9] vs. 0.5 [95% CI: 0.1-1.0], p = 0.004), demonstrating Mediterranean diet feasibility. There was a greater proportion of gastrointestinal symptom responders in the Mediterranean diet group than controls (24/29, 83% vs. 11/30, 37%, p < 0.001) and depression responders (15/29, 52% vs. 6/30 20%, p = 0.015). There was no difference in FODMAP intake at week 6 (p = 0.51). Gastrointestinal adverse events were similar (p = 0.588). There were no differences in change in microbiome parameters between groups. CONCLUSIONS: A Mediterranean diet is feasible in IBS and leads to improvement in gastrointestinal and psychological symptoms. Although this study was unblinded, these findings together with the broader benefits of the Mediterranean diet, provide strong impetus for future research in IBS. Australia New Zealand Clinical Trials Registry: ACTRN12620001362987.
引用
- Staudacher HM, Mahoney S, Canale K, et al. Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2023. PMID: 37969059. doi:10.1111/apt.17791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。